Entecapone

Class Antiparkinsonian agent
Chemistry

Nitrocatechol

Routes of administration

oral

Absorption

Oral bioavailability 35%

Solubility

pKa = 4.5, practically insoluble in water

Distribution

VOD= 0.3L/kg, 98% protein-bound

Metabolism

hepatic metabolism - primarily metabolised to its glucuronide

Elimination

Minimal free drug is eliminated in the urine

Time course of action

Half-life 1.-0-2.5 hours

Target receptor

Catechol-O-methyl transferase (which it inihibits)

Mechanism of action

By inhibiting COMT, entecapone prevents the peripheral metabolism of L-dopa, and is an adjunct to LD and a peripherally acting dopa decarboxylase inhibitor. It has no antiParkinsonian activity of its own.

Clinical effects

Apart from its desiable effecst 9proloning the effects of levodopa), entacapone can increase dyskineasias, and produce diarrhoea. Hypertension is not usually seen unless there is sufficient noradrenaline or adrenaline being released for some other reason. Also it can turn your urine black or brown.

Literature reference

Habet, 2022

CICM details of understanding Not specifically listed in the CICM syllabus
Mentioned around Deranged Physiology
Related SAQs